Treating Multiple Myeloma in Latin America
Interactive discussions and expert insights on the latest updates and remaining challenges
Overview
In recent years, progress in the understanding of multiple myeloma has led to novel therapies that are rapidly changing treatment paradigms. Aptitude Health developed the Global Multiple Myeloma Academy to help physicians who treat multiple myeloma bridge the gap between innovation and implementation of patient care.
Date and Location
23–24 June 2022, Virtual Meeting
Chair
Rafael Fonseca, MD
Mayo Clinic Cancer Center, USA
Faculty
Keith Stewart, MBChB, MBA
Princess Margaret Cancer Centre, Canada
Sagar Lonial, MD, FACP
Emory University School of Medicine, USA
Vania Hungria, MD
São Germano Clinic, Brazil
Eloisa Riva, MD
Hospital de Clínicas, Montevideo, Uruguay
Luciano J. Costa, MD, PhD
University of Alabama, Birmingham, USA
|
Agenda |
This virtual program was held over 2 days. |
Day 1: Thursday, 23 June 2022
11.30 AM – 3.00 PM (MST/Arizona)
1.30 PM – 5.00 PM (GMT-5/Colombia)
2.30 PM – 6.00 PM (GMT-4/Chile)
3.30 PM – 7.00 PM (GMT-3/Brazil)
| Time (UTC -3) | Topic | Speaker |
| 3.30 PM – 3.40 PM | Welcome and Meeting Overview • Introduction to audience response system (ARS) |
Rafael Fonseca, MD |
| 3.40 PM – 4.00 PM | Diagnosis and Risk Stratification of Multiple Myeloma • Prognostic value, clinical relevance, and response-adapted therapeutic strategies |
Vania Hungria, MD, PhD |
| 4.00 PM – 4.25 PM | Smoldering Multiple Myeloma: Current and Future Developments • Diagnosis, criteria, and pragmatic treatment approaches |
Sagar Lonial, MD, FACP |
| 4.25 PM – 4.50 PM | Newly Diagnosed Transplant-Eligible Multiple Myeloma: Frontline Therapy and the Role of Transplantation • Updates, induction therapies, and knowing when to transplant |
Luciano Costa, MD, PhD |
| 4.50 PM – 5.10 PM | Debate • Is myeloma curable or not? |
Rafael Fonseca, MD (yes) vs Eloisa Riva, MD (no) |
| 5.10 PM – 5.20 PM | Break | |
| 5.20 PM – 5.45 PM | Advances in Consolidation and Maintenance Therapy: Latest Updates and MRD-Guided Therapy • Evolving insights in consolidation and maintenance treatment after transplant |
Luciano Costa, MD, PhD |
| 5.45 PM – 6.10 PM | Treatment Considerations for Newly Diagnosed Transplant-Ineligible Patients • Criteria, guidelines, and treatment choices |
Keith Stewart, MBChB, MBA |
| 6.10 PM – 6.35 PM | Interactive Discussion and Q&A • Regional challenges of MM diagnosis (2–3 questions to trigger discussion, no presentation slides) • Questions from audience |
All faculty discussion |
| 6.35 PM – 6.55 PM | Debate • Smoldering myeloma: To treat or not to treat? |
Sagar Lonial, MD, FACP (yes) vs Keith Stewart, MBChB, MBA (no) |
| 6.55 PM – 7.00 PM | Session Close • ARS questions |
Rafael Fonseca, MD |
Day 2: Friday, 24 June 2022
11.30 AM – 3.00 PM (MST/Arizona)
1.30 PM – 5.00 PM (GMT-5/Colombia)
2.30 PM – 6.00 PM (GMT-4/Chile)
3.30 PM – 7.00 PM (GMT-3/Brazil)
| Time (UTC-3) | Topic | Speaker |
| 3.30 PM – 3.40 PM | Session Open | Rafael Fonseca, MD |
| 3.40 PM – 4.00 PM | Defining and Understanding High-Risk Multiple Myeloma • Risk stratification, prognosis, and therapy choices |
Eloisa Riva, MD |
| 4.00 PM – 4.25 PM | Early Relapse of Multiple Myeloma: Current and Emerging Treatment Options • Definition, prognosis, updated treatment approaches |
Rafael Fonseca, MD |
| 4.25 PM – 4.45 PM | Patient Case Discussion and Q&A: Relapsed/Refractory Multiple Myeloma • Case 1 from the region |
Regional case presenter Ana Luiza Silva, MD |
| 4.45 PM – 4.55 PM | Break | |
| 4.55 PM – 5.20 PM | Management of Heavily Pretreated Multiple Myeloma • Optimal use of treatment choices in relapsed/refractory multiple myeloma |
Keith Stewart, MBChB, MBA |
| 5.20 PM – 5.40 PM | Patient Case Discussion and Q&A: Relapsed/Refractory Multiple Myeloma • Case 2 from the region |
Regional case presenter Lucía Pérez, MD |
| 5.40 PM – 6.30 PM | Beyond the Horizon: New and Future Multiple Myeloma Treatment Approaches • Optimal use of treatment choices in relapsed/refractory multiple myeloma – Bispecifics in multiple myeloma – CAR Ts in multiple myeloma |
Vania Hungria, MD, PhD (bispecifics), Luciano Costa, MD, PhD (CAR T) |
| 6.30 PM – 6.55 PM | Interactive Discussion and Q&A • Treatment landscape evolution (2–3 questions to trigger discussion, no presentation slides) • Questions from audience |
All faculty discussion |
| 6.55 PM – 7.00 PM | Session Close | Rafael Fonseca, MD |
